- 1 **Title:** Distinct respiratory tract biological pathways characterizing ARDS molecular
- 2 phenotypes
- 3 Authors: Aartik Sarma¹, Stephanie A. Christenson¹, Beth Shoshana Zha¹, Angela Oliveira
- 4 Pisco², Lucile P.A. Neyton¹, Eran Mick^{2,3}, Pratik Sinha⁴, Jennifer G. Wilson⁵, Farzad Moazed¹,
- 5 Aleksandra Leligdowicz^{6,7}, Manoj V. Maddali⁸, Emily R. Siegel⁹, Zoe M. Lyon⁹, Hanjing Zhou¹,
- 6 Alejandra Jauregui¹, Rajani Ghale¹, Saharai Caldera², Paula Hayakawa Serpa^{2,3}, Thomas
- 7 Deiss¹, Christina Love², Ashley Byrne², Katrina L. Kalantar², Joseph L. DeRisi², David J.
- 8 Erle^{6,10,11,12}, Matthew F. Krummel^{11,13}, Kirsten N. Kangelaris¹⁴, Carolyn M. Hendrickson¹⁵,
- 9 Prescott G. Woodruff^{1,6}, COMET Consortium, Michael A. Matthay^{1,6,16}, Charles R. Langelier^{2,3},
- 10 Carolyn S. Calfee^{1,6,16}

11 Affiliations:

- Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California San Francisco, CA
- 14 2. Chan Zuckerberg Biohub, San Francisco, CA
- Division of Infectious Diseases, Department of Medicine, University of California San
 Francisco, CA
- 17 4. Department of Anesthesia, Washington University in St Louis
- Department of Emergency Medicine, Stanford University School of Medicine, Stanford
 University, Stanford, CA
- 20 6. Cardiovascular Research Institute, University of California San Francisco, CA
- Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto,
 Ontario, Canada
- B. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine,
 Stanford University, Stanford, CA
- 25 9. School of Medicine, University of California San Francisco, CA
- 26 10. Lung Biology Center, University of California San Francisco, CA
- 27 11. Bakar ImmunoX Initiative, University of California San Francisco, CA
- 28 12. UCSF CoLabs, University of California San Francisco, CA
- 13. Department of Pathology, University of California San Francisco, CA
- 30 14. Division of Hospital Medicine, University of California San Francisco, CA
- 15. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Zuckerberg
 San Francisco General Hospital and Trauma Center, University of California San
 Francisco
- 34 16. Department of Anesthesia, University of California San Francisco, CA
- 35
- 36 Word count: 3,493

37 Abstract:

38 Background: Two molecular phenotypes of the acute respiratory distress syndrome (ARDS) 39 with divergent clinical trajectories and responses to therapy have been identified. Classification 40 as "hyperinflammatory" or "hypoinflammatory" depends on plasma biomarker profiling. Differences in pulmonary biology underlying these phenotypes are unknown. 41 42 Methods: We analyzed tracheal aspirate (TA) RNA sequencing (RNASeg) data from 41 ARDS 43 patients and 5 mechanically ventilated controls to assess differences in lung inflammation and 44 repair between ARDS phenotypes. In a subset of subjects, we also analyzed plasma proteomic 45 data. We performed single-cell RNA sequencing (scRNASeq) on TA samples from 9 ARDS 46 patients. We conducted differential gene expression and gene set enrichment analyses, in silico 47 prediction of pharmacologic treatments, and compared results to experimental models of acute 48 lung injury. 49 Findings: In bulk RNASeg data, 1334 genes were differentially expressed between ARDS 50 phenotypes (false detection rate < 0.1). Hyperinflammatory ARDS was characterized by an 51 exaggerated innate immune response, increased activation of the integrated stress response, 52 interferon signaling, apoptosis, and T-cell activation. Gene sets from experimental models of 53 lipopolysaccharide lung injury overlapped more strongly with hyperinflammatory than 54 hypoinflammatory ARDS, though overlap in gene expression between experimental and clinical 55 samples was variable. ScRNASeg demonstrated a central role for T-cells in the 56 hyperinflammatory phenotype. Plasma proteomics confirmed a role for innate immune 57 activation, interferon signaling, and T-cell activation in the hyperinflammatory phenotype. 58 Predicted candidate therapeutics for the hyperinflammatory phenotype included imatinib and 59 dexamethasone. 60 Interpretation: Hyperinflammatory and hypoinflammatory ARDS phenotypes have distinct 61 respiratory tract biology, which could inform targeted therapeutic development.

- 62 **Funding:** National Institutes of Health; University of California San Francisco ImmunoX
- 63 CoLabs; Chan Zuckerberg Foundation; Genentech
- 64
- 65 Abstract word count: 246 without funding

66 Introduction

67	The acute respiratory distress syndrome (ARDS) is characterized by noncardiogenic
68	pulmonary edema and hypoxemia within one week of a physiologic insult ¹ . The global incidence
69	of ARDS has surged during the COVID-19 pandemic, increasing the importance of finding
70	effective treatments. While some pharmacologic interventions have decreased mortality in
71	patients with severe COVID-19 ^{2,3} , no drug has consistently reduced mortality in more typical
72	heterogeneous cohorts of patients with ARDS. There is a growing recognition that biological
73	heterogeneity within the syndrome is a significant barrier to identifying effective treatments ⁴ .
74	Two clinically distinct molecular phenotypes of ARDS (termed "hyperinflammatory" and
75	"hypoinflammatory") have been identified using latent class analysis of clinical and plasma
76	biomarker data in eight cohorts ^{1,5–11} . The hyperinflammatory phenotype is characterized by
77	elevated plasma inflammatory cytokines (IL-8, IL-6, TNFr-1), lower plasma Protein C and
78	bicarbonate, and higher mortality compared to the hypoinflammatory phenotype. Importantly,
79	significant differences in treatment response to simvastatin, ventilator settings, and fluid
80	management have been observed across molecular phenotypes in retrospective analyses of
81	three ARDS clinical trials ^{5,6,11} ; further, in patients with COVID-19-related ARDS,
82	hyperinflammatory patients may preferentially respond to corticosteroid treatment ^{12,13} . These
83	results suggest that understanding and targeting the heterogeneous biology underlying ARDS
84	molecular phenotypes is essential to identifying effective new treatments for ARDS. Prospective
85	studies designed to identify these phenotypes using parsimonious models are laying the
86	groundwork for precision clinical trials ^{4,14} .
87	Despite this exciting progress, a critical barrier to developing new therapies for ARDS is
88	the limited understanding of the biological pathways characterizing each phenotype. This
89	knowledge gap was recently cited by NHLBI and European Respiratory Society workshops on
90	precision medicine in ARDS as a top research priority for the field ^{4,15} . To date, analyses of the
91	biological differences between these phenotypes have been largely limited to circulating

biomarkers, due to the relative ease of sampling. Understanding the biological differences
between ARDS molecular phenotypes in the lung, the active site of injury, will be critical to
development of informative pre-clinical models of disease and targeted treatments for ARDS.
Here, we employ a systems biology approach incorporating bulk and single-cell RNAsequencing, *in silico* analyses, and proteomics to understand differences in lung immunology
and inflammatory responses between ARDS phenotypes.

98

99 Methods:

100 Study subjects

101 Subjects were enrolled in two prospective observational cohorts of critically ill patients. 102 We used bulk RNASeg data and plasma proteomic data from the Acute Lung Injury in Critical 103 Illness (ALI) study, a cohort of mechanically ventilated adults admitted to the intensive care unit 104 at the University of California, San Francisco Medical Center (UCSFMC) between July 2013 and 105 March 2020. We used single-cell RNA-Sequencing (scRNASeq) data from the COVID-19 106 Multiphenotyping for Effective Therapies (COMET) study, a study of hospitalized patients with 107 COVID-19 or other acute respiratory illnesses admitted to UCSFMC or Zuckerberg San 108 Francisco General Hospital (ZSFGH). COVID-19 status was confirmed by clinical PCR testing 109 and metagenomic sequencing. These studies were approved by the UCSF Institutional Review 110 Board (17-24056, 20-30497), which granted an initial waiver of informed consent to collect TA 111 and blood samples. Informed consent was then obtained from patients or surrogates, as 112 previously described¹⁶. 113 In this analysis, we included all available subjects in each cohort who were admitted to

the intensive care unit for mechanical ventilation for ARDS or for airway protection without radiographic evidence of underlying pulmonary disease. For non-ARDS control patients in the ALI study, we excluded subjects on immunosuppression, including corticosteroids, and those with immunocompromising conditions (e.g., bone marrow transplant recipients).

118

119 **ARDS** adjudication and phenotype assignment

120 Electronic health records were adjudicated for ARDS (Berlin Definition¹⁷) by at least two 121 clinicians blinded to all biological data. Lower respiratory tract infections were diagnosed using the CDC surveillance definition¹⁸. ARDS phenotype was determined using a validated three-122 variable classifier model (IL-8, protein C, and bicarbonate)¹⁴. Subjects with a probability of class 123 124 assignment greater than 0.5 were assigned to the hyperinflammatory phenotype. Plasma 125 biomarkers were not available for five subjects with TA bulk RNA sequencing. For these subjects, we used a validated clinical classifier model to assign phenotype^{10,19}. 126 127 128 Tracheal aspirate sampling and RNA sequencing 129 Following enrollment in the ALI cohort, TA was collected within three days of intubation. 130 In the COMET cohort, TA samples were collected daily, and the first available sample collected 131 within three days of enrollment was used for this analysis. For bulk RNA sequencing, TA was collected and stored in DNA/RNA Shield (Zymo, Inc.) at -80C¹⁶. Samples underwent library 132 133 preparation and Illumina paired-end sequencing using established methods described in detail 134 in the online supplement. For scRNASeq, TA was collected and processed within 3 hours as 135 previously described²⁰.

136

137 Cell annotation, differential expression, pathway, and network analysis

We performed pairwise comparisons of gene expression in each ARDS phenotype and controls using *DESeq2*. Single cell transcriptomes were annotated using *SingleR*. We compared gene expression between phenotypes for each cell type using *MAST*, using a mixed effects model with fixed effects for phenotype and cellular detection rate and a random effect for subject. Differentially expressed genes were then analyzed using Ingenuity Pathway Analysis (IPA, Qiagen). Full details of cell annotation, differential gene expression, and IPA analyses are

144	provided in the online supplement. To study how cell-cell signaling contributed to observed
145	differential expression, we used <i>CellChat</i> ²¹ to infer intercellular communication networks by
146	comparing scRNASeq data to a curated database of ligands, receptors, and their cofactors.
147	
148	Plasma proteomic analysis
149	Plasma samples from the Acute Lung Injury in Critical Illness cohort and 14 healthy
150	controls from a previously published dataset ²² were analyzed using the O-link Proteomics
151	Assay, which generates a semi-quantitative measurement of 96 plasma proteins. We excluded
152	all samples that were flagged with a QC warning from the O-link platform and excluded any
153	biomarker for which protein concentrations could not be measured for at least 90% of samples.
154	Measurements for 73 proteins passed the manufacturer's quality control filter and were included
155	for analysis. Normalized protein expression measurements were compared using a Wilcoxon
156	rank-sum test and p-values were adjusted using the Benajmini-Hochberg method (FDR < 0.1).
157	
158	Comparison of differentially expressed genes to experimental models of acute lung
159	injury
160	We identified experimental models of acute lung injury in the Gene Expression Omnibus.
161	Lists of all genes differentially expressed at a Benjamini-Hochberg adjusted p-value less than
162	0.05 were downloaded using GEO2Enrichr ²³ . We then used the genes that were upregulated in
163	the experimental lung injury model as gene signatures in GSVA ²⁴ (Supplemental Data 3A). If
164	more than 200 genes were differentially expressed in the experimental model, we used the top
165	200 genes (by p-value) for the experimental gene signature. We used <i>limma</i> ²⁵ to compare
166	GSVA scores in samples from each phenotype to GSVA scores in controls.
167	
168	Results

169 Patient Characteristics: Acute Lung Injury in Critical Illness Cohort

In the Acute Lung Injury in Critical Illness cohort, TA sequencing data was available for
41 ARDS participants and five controls (Figure S1). Ten of 41 ARDS subjects (24%) were
classified as the hyperinflammatory phenotype, consistent with the proportion observed in
previous studies^{5–8,11}. There were no significant differences in age, sex, BMI,
immunosuppression, respiratory viral or bacterial infections, or ARDS risk factors between
hyperinflammatory and hypoinflammatory patients (Table 1).

176

177 Bulk RNA-Sequencing

178 1,334 genes were differentially expressed between ARDS phenotypes with an absolute 179 empirical Bayesian posterior log₂-fold change >0.5 (Figure S2A, Supplementary Data S1A). IPA 180 predicted increased activation of several cytokines and other upstream regulators of 181 differentially expressed genes in hyperinflammatory ARDS, compared with hypoinflammatory 182 ARDS (Figure 1A, Supplementary Data S2A). These included several cytokines classically 183 associated with an innate response previously found to be elevated in plasma of patients with 184 hyperinflammatory ARDS, including IL1B, IL6, and TNF. In addition, IPA identified activation of 185 cytokine responses not previously studied in hyperinflammatory ARDS, including numerous 186 interferon-stimulated genes; IL2 and IL15, which stimulate cytotoxic T cell and NK cell 187 responses²⁶; and the chemokine ligand CCL2/MCP-1. Upstream regulator analysis predicted 188 increased activation of transcriptional regulators critical to the integrated stress response 189 (XBP1, NFE2L2) and increased cellular differentiation (MYC, NONO), as well as stimulation of 190 Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) and receptors integral to T cell activation 191 (CD3, CD28) in hyperinflammatory ARDS.

To further understand how pathways in each phenotype were dysregulated, we
compared each phenotype to mechanically ventilated control patients with neurologic injury.
2,989 genes were differentially expressed between hyperinflammatory ARDS and controls
(Figure S2B, Supplementary Data 1C), while 2,132 genes were differentially expressed between

196 hypoinflammatory ARDS and controls (Figure S2C, Supplementary Data 1D). Notably, 197 upstream regulator analysis identified several cytokines that were activated in both 198 hyperinflammatory and hypoinflammatory ARDS compared to controls (Figure 1C, 199 Supplementary Data 2C and 2D), including IL1B, TNF, and IFNG. While this analysis identified 200 some similarities between phenotypes, it also confirmed that several upstream regulators that 201 were activated in pairwise comparisons of hyperinflammatory ARDS to hypoinflammatory ARDS 202 and hyperinflammatory ARDS to controls, suggesting these upstream regulators play an 203 important role in the distinct features of hyperinflammatory ARDS. These included IL6, which was one of plasma cytokines used to define the hyperinflammatory phenotype⁵; IL18, which was 204 205 not measured in the original LCA studies, but, like the hyperinflammatory phenotype, was associated with higher mortality and a response to simvastatin in the HARP-2 trial²⁷; the T cell 206 207 receptor; Type I/III interferons (IFNA, IFNL, IFNB), indicative of an enhanced mucosal interferon response²⁸; several Toll-like receptors (TLR2/3/9); and FAS, which stimulates apoptosis²⁹. In 208 209 addition, several upstream regulators associated with specific immune cells were predicted to 210 be activated in hyperinflammatory ARDS but not in hypoinflammatory ARDS, including markers of activated T cells (NFATC1³⁰), NK cells (NCR1³¹, KLRK1³²), and platelets (PF4³³), suggesting 211 212 these cells play a key role in the distinct biology of hyperinflammatory ARDS.

213

214 Alignment with Experimental Models of Lung Injury

IPA identified lipopolysaccharide (LPS), a component of gram-negative bacteria, as an
 upstream regulator of genes differentially expressed between ARDS phenotypes
 (Supplementary Data S2A) and in comparisons of each ARDS phenotype to controls

218 (Supplementary Data S2C and S2D). We hypothesized that genes upregulated in LPS models

of lung injury would be more upregulated in hyperinflammatory ARDS compared to controls than

- in hypoinflammatory ARDS compared to controls. Respiratory tract gene expression data was
- available from four LPS models of ARDS in the Gene Expression Omnibus. We also identified

222	17 more datasets from other experimental models of ARDS including ventilator-induced lung
223	injury (VILI), ozone, hyperoxia, Pam3Cys (a TLR2 agonist), and hemorrhagic shock
224	(Supplementary Data S3A). Gene sets from four models were significantly enriched (FDR < 0.1)
225	in TA from both ARDS phenotypes (Figure 1B; Supplementary Data S3B and S3C). As
226	expected, LPS models had a significant overlap with both phenotypes, but LPS experimental
227	gene sets had higher GSVA scores in hyperinflammatory participants. In addition, gene sets
228	from two ozone models, two LPS models, and one VILI model were enriched in
229	hyperinflammatory ARDS but not in hypoinflammatory ARDS, suggesting these models better
230	replicated dysregulated gene expression observed in the hyperinflammatory phenotype.
231	
232	In silico analysis of candidate drugs for hyperinflammatory ARDS
233	To identify candidate treatments for the hyperinflammatory ARDS phenotype, we used
234	Upstream Regulator Analysis to identify drugs predicted to decrease expression of genes
235	upregulated in hyperinflammatory ARDS compared to hypoinflammatory ARDS or controls
236	(Figure 1C). For example, dexamethasone, which decreases interferon-gamma signaling ³⁴ , was
237	predicted to shift gene expression away from hyperinflammatory ARDS. Interestingly, several
238	drugs which cause drug-induced pneumonitis (e.g., nitrofurantoin, amiodarone, and cytarabine)
239	were predicted to shift gene expression from controls toward hyperinflammatory ARDS
240	(Supplementary Data S2C).
241	
242	Single-cell RNA-sequencing
243	We used a neutrophil-preserving scRNASeq method to study TA from nine COVID-

negative patients with ARDS enrolled in a separate observational cohort (COMET; described in
 Methods). TA scRNASeq was available from five participants with hypoinflammatory ARDS and
 four with hyperinflammatory ARDS; clinical characteristics of these patients are provided in

Supplementary Table 1. 26,429 cells passed quality filters, and we used SingleR³⁵ to identify 247 cell types (Figure 2A). Neutrophils were the most common cell in both phenotypes (Figure 2B), 248 249 CellChat predicted markedly higher interaction between T cells and other cell types in 250 the hyperinflammatory phenotype (Figure 2C), which was consistent with the bulk analysis 251 predicting increased T cell activation. Phenotype-specific differences in cell-cell signaling were 252 driven by ligand-receptor pairs in several pathways (Figure 2D; Supplementary Figure 6A and 253 6B). In the hyperinflammatory phenotype, *CellChat* predicted increased MHC-I signaling, which 254 was driven by increased signaling to CD8 on T cells and NK cells. In contrast, MHC-II activity 255 was predicted to be higher in hypoinflammatory ARDS. CellChat also identified increased 256 NAMPT signaling by NK and T cells to integrin \Box 5 β 1 on monocytes, macrophages, and 257 dendritic cells in hyperinflammatory ARDS (Supplementary Data 6). Notably, NAMPT 258 polymorphisms are associated with a 7.7-fold increased risk of sepsis-associated ARDS³⁶ and 259 NAMPT was identified as an upstream regulator of differential gene expression in our bulk 260 RNASeq data (Figure 1C). These results further supported the hypothesis that there are marked 261 differences in respiratory tract signaling between phenotypes driven by differences in T and NK 262 cell signaling.

263 We next used MAST to compare differential gene expression in TA neutrophils, T cells, 264 monocyte-derived macrophages, and monocytes (Supplementary Figure 4, Supplementary 265 Data S4). We used IPA to identify upstream regulators of gene expression and analysis 266 identified several cell-specific differences in gene expression (Figure 2E, Supplementary Data 267 S5). Notably, some cytokines that were predicted to be activated in hyperinflammatory ARDS in 268 the bulk RNA sequencing data, including TNF and IFNG, were relatively less active in 269 neutrophils and monocytes from hyperinflammatory TA samples. In contrast, interferon lambda, 270 which is produced by the respiratory epithelium, was predicted to be more activated in 271 hyperinflammatory neutrophils and T cells. IPA also predicted increased activation of cell

activation of the integrated stress response (XBP1, EIF2AK2) and TLR4 in T cells from the
hyperinflammatory phenotype (Supplementary Data S5D).

274

275 Plasma proteomic analysis identifies additional cytokines upregulated in

276 hyperinflammatory ARDS

To further validate the biologic relevance of the TA findings, we measured plasma concentrations of 96 protein biomarkers. 21 participants included in the TA bulk sequencing analysis had protein biomarker data available, as did four participants from the same cohort who did not have TA bulk sequencing available. Of these 25 participants, five had hyperinflammatory ARDS and 20 had hypoinflammatory ARDS (Supplementary Table 2). We compared these subjects to 14 healthy controls (mean age: 38, 43% female) and included in a previously published analysis²².

284 Plasma concentrations of 28 proteins were higher in hyperinflammatory ARDS than in 285 hypoinflammatory ARDS (FDR < 0.1, Figure 3A). Some of these biomarkers confirmed known 286 differences between phenotypes, including higher concentrations of IL6 and TNF in 287 hyperinflammatory ARDS. Nine of these biomarkers were also elevated in hyperinflammatory 288 ARDS compared to controls but were not elevated in hypoinflammatory ARDS (Figure 3B and 289 3C), suggesting they identify distinctly dysregulated pathways in the hyperinflammatory 290 phenotype. These proteins included IL-8, which is one of the cytokines that defines the hyperinflammatory phenotype; CASP-8, an effector of FAS signaling³⁷; interferon-induced 291 292 proteins CXCL9 and CXCL10³⁸; plasma urokinase (uPA); oncostatin M; and adenosine deaminase (ADA). In addition, CCL2/MCP-1 and the T cell activation marker CD5³⁹ were higher 293 294 in hyperinflammatory ARDS and in controls compared to hypoinflammatory ARDS. These 295 observations were consistent with differences in TA gene expression at both the bulk RNASeq 296 and scRNASeg level. Plasma proteins that were higher in controls than in ARDS subjects are 297 shown in Supplementary Figure S7.

298

299 **Discussion**

300 This analysis represents the first report of significant differences in pulmonary biology 301 between ARDS molecular phenotypes, which have previously been characterized primarily 302 using plasma biomarkers. In addition to confirming evidence of innate immune activation 303 suggested by prior data on circulating plasma biomarkers, these analyses identify several novel 304 pathways as relevant to the pathogenesis of hyperinflammatory ARDS, including interferon-305 stimulated pathways, apoptosis, and T-cell signaling, and suggest that each ARDS phenotype 306 has distinct pulmonary pathobiology which could help identify new therapeutic targets. 307 We identified a central role of T and NK cells in coordinating dysregulated inflammation 308 in hyperinflammatory ARDS. Hyperinflammatory ARDS was associated with markedly higher 309 mucosal interferon-stimulated gene expression and T/NK cell activation in bulk sequencing of 310 TA. Network analysis of scRNASeq data was also consistent with a central role of T and NK 311 cells in hyperinflammatory ARDS. These analyses identified differences in APC to T/NK cell 312 signaling, with greater MHC-I to CD8 signaling in the hyperinflammatory phenotype. Single cell 313 differential expression also predicted increased activation of TLR4 and XBP1 in 314 hyperinflammatory ARDS, suggesting the integrated stress and innate immune responses are 315 upregulated in T cells from the hyperinflammatory phenotype. In contrast to prior literature on 316 ARDS^{40,41}, which has emphasized the role of neutrophils, activated macrophages, and alveolar 317 epithelial cells in ARDS pathogenesis, our observations suggest lymphocytes play an 318 underrecognized role in coordinating dysregulated inflammation in hyperinflammatory ARDS. 319 Some features that characterized the hyperinflammatory phenotype in bulk sequencing 320 (e.g., higher predicted activation of cytokines classically associated with an innate response) 321 were not observed in specific cell types in scRNASeq. This observation has several possible 322 explanations. First, the results in bulk RNA sequencing may be driven by differences in the 323 immune cell composition of TA in each phenotype, as suggested by our scRNASeg analyses.

Notably, a similar pattern of high interferon-stimulated gene expression in T cells but diminished immune responses in macrophages has also been reported in severe COVID-19⁴². Second, the bulk signals may be driven by highly activated cells that do not survive the scRNASeq processing pipeline, as has been reported previously for activated macrophages and neutrophils. Third, some signals observed in the bulk data may be driven by epithelial cells, which were selected against in our scRNASeq pipeline (in favor of enriching for immune cell populations) and are thus not well-represented.

331 Plasma proteomics identified increased concentrations of the interferon-stimulated 332 proteins CXCL9 and CXCL10 and the T cell activation marker CD5 in hyperinflammatory ARDS 333 but not in hypoinflammatory ARDS. Notably, in an alternative molecular phenotyping approach 334 that used k-means clustering of plasma biomarkers to categorize ARDS subjects into two 335 molecular phenotypes ("reactive" and "uninflamed"), plasma IFNy is one of the defining biomarkers of the higher mortality "reactive" phenotype⁴³. Taken together, these analyses 336 337 support a central role of mucosal interferons and T cell activation in hyperinflammatory ARDS. 338 To our knowledge, only one prior study has attempted to characterize the pulmonary compartment in ARDS phenotypes⁴⁴. This study included 10 hypoinflammatory patients and 16 339 340 hyperinflammatory patients and found no difference between these groups in concentration of 341 several inflammatory protein biomarkers in mini-BAL samples or in the lung microbiome. Our 342 results may differ from these because of a larger sample size, differing analytic approaches, 343 differing sampling strategies, or some combination thereof.

We compared differentially expressed genes in clinical samples to experimental ARDS models to determine the relevance of these models to each phenotype. An experimental model combining intratracheal LPS *and* mechanical ventilation was the murine model with the strongest overlap in gene expression with ARDS subjects in both phenotypes. This gene signature was from an experiment demonstrating that a combined MV/LPS model generated markedly higher neutrophilic inflammation in the lung than LPS or MV alone⁴⁵. In addition, gene

350 signatures from five LPS models were enriched in hyperinflammatory ARDS but were not enriched in hypoinflammatory ARDS, suggesting that hypoinflammatory patients, on average, 351 352 have less of an overlap in respiratory biology with the preclinical models. Our results also 353 indicate that the overlap in gene expression between experimental models and clinical samples 354 is highly variable, even among models with similar injurious stimuli (e.g., among VILI models). 355 Further study is required to understand how best to model each phenotype experimentally and if 356 our observations partially explain why therapies that appear promising in pre-clinical models are 357 not effective in more heterogeneous clinical trial populations.

358 Our results have important implications for developing a precision approach to treating 359 ARDS⁴. The *in silico* analysis identified several candidate therapies that target the dysregulated 360 pathways identified in hyperinflammatory ARDS. Several of the candidate drugs, including 361 imatinib, dexamethasone, and metformin, decrease lung injury caused by LPS in experimental 362 models⁴⁶⁻⁴⁸, again suggesting LPS replicates important features of the hyperinflammatory 363 phenotype. Approximately one-third of candidate drugs identified using pathway analyses are validated in *in* vivo⁴⁹ and these treatments require validation in further preclinical studies and 364 365 clinical trials.

366 Strengths of this study include transcriptomic analysis of samples from the focal organ of 367 injury in ARDS, providing a detailed picture of the pulmonary biology of both ARDS phenotypes, 368 and deepening of these observations with single-cell sequencing and peripheral blood 369 proteomics. The inclusion of non-ARDS ventilated controls allowed us to further characterize the 370 physiologic dysregulation in the phenotypes, rather than defining gene expression relative to 371 another pathologic state. This analysis also has some limitations. Bulk and single-cell RNASeq 372 samples were collected in separate cohorts, so we cannot integrate these analytical approaches. Although TA contains fluid from the distal airspaces⁵⁰, more invasive BAL testing 373 374 may identify additional differences between the phenotypes.

- 375 In conclusion, an integrated, multi-omic analysis of ARDS molecular phenotypes
- 376 originally defined by clinical and plasma protein biomarkers suggests the hyperinflammatory
- 377 phenotype is characterized by increased interferon-stimulated gene expression coordinated by
- 378 T cell signaling in the lower respiratory tract. Our findings suggest that the respiratory tract
- 379 biology of these phenotypes is distinct and further supports the use of molecular phenotypes to
- 380 study acute lung injury biology and develop new treatments for ARDS.

381

382 Materials and Methods

- 383 List of Supplementary Materials
- **Figure S1:** Subjects included in this analysis.
- 385 **Figure S2:** Volcano plots showing differential gene expression between (A) 10
- 386 hyperinflammatory ARDS and 31 hypoinflammatory ARDS subjects, (B) 10 hyperinflammatory
- 387 ARDS and 5 control subjects, and (C) 31 hypoinflammatory ARDS and 5 control subjects.
- 388 **Figure S3:** GSVA scores for signatures of ALI experimental models in TA transcriptomes from 5
- 389 control subjects, 31 hypoinflammatory ARDS subjects, and 10 hyperinflammatory ARDS
- 390 subjects.
- 391 **Figure S4:** Volcano plots showing differential gene expression in scRNASeq for 5
- 392 hypoinflammatory ARDS subjects and 4 hypoinflammatory ARDS subjects in the COMET
- 393 cohort.
- **Figure S5**: Circos plots displaying differentially interactive ligand-receptor pairs identified by
- 395 CellChat in a comparison of scRNASeq from 5 hypoinflammatory and 4 hyperinflammatory
- ARDS subjects. (A) Pairs that are relatively higher in hyperinflammatory ARDS and (B) Pairs
- 397 that are relatively higher in hypoinflammatory ARDS.
- **Figure S6**: Heatmaps for plasma proteins that are significantly higher in (A) Controls vs.
- 399 hyperinflammatory ARDS and (B) Controls vs. hypoinflammatory ARDS
- 400 **Figure S7**: Heatmap showing estimated power to detect a difference between phenotypes in
- 401 the Acute Lung Injury in Critical Illness cohort based on effect size and within-group coefficient402 of variation.

403

404 Supplementary Data S1: Differential gene expression for pairwise comparisons of bulk RNA

405 gene expression for TA in the Acute Lung Injury in Critical Illness cohort. A positive log₂ fold

406 difference indicates the gene is more highly expressed in the first group compared to second

407	group for each comparison. (A) Hyperinflammatory ARDS vs. hypoinflammatory ARDS; (B)
408	Hyperinflammatory ARDS vs. hypoinflammatory ARDS after adjusting for fungal infections; (C)
409	Hyperinflammatory ARDS vs. controls; and (D) Hypoinflammatory ARDS vs. controls; and (E)
410	All ARDS subjects vs. controls.
411	
412	Supplementary Data S2: IPA Upstream Regulator scores for pairwise comparisons of bulk
413	RNA gene expression for TA in the Acute Lung Injury in Critical Illness Cohort. A positive z-
414	score indicates gene expression is consistent with higher activity of the upstream regulator in
415	the first group compared to second group for each comparison. (A) Hyperinflammatory ARDS
416	vs. hypoinflammatory ARDS; (B) Hyperinflammatory ARDS vs. controls; (C) Hypoinflammatory
417	ARDS vs. controls; and (D) All ARDS vs. controls.
418	
419	Supplementary Data S3: (A) 200 most upregulated genes in experimental models of lung injury
420	compared to controls for 21 experimental systems in the Gene Expression Omnibus. (B) Gene
421	set enrichment analysis scores and leading-edge genes for experimental model gene sets in TA
422	differential expression for hyperinflammatory ARDS vs. controls. (C) Gene set enrichment
423	analysis scores and leading-edge genes for experimental model gene sets in TA differential
424	expression for hypoinflammatory ARDS vs. controls.
425	
426	Supplementary Data S4: Differential gene expression for single-cell RNA sequencing for TA
427	for the COMET cohort. A positive log_2 fold difference indicates the gene is more highly
428	expressed in hyperinflammatory ARDS. (A) Neutrophils, (B) Monocytes, (C) Monocyte-derived
429	macrophages, (D) T cells
430	
431	Supplementary Data S5: IPA Upstream Regulator scores for pairwise comparisons of bulk

432 RNA gene expression for TA in the COMET. A positive z-score indicates gene expression is

- 433 consistent with higher activity of the upstream regulator in the hyperinflammatory ARDS
- 434 samples. (A) Neutrophils, (B) Monocytes, (C) Monocyte-derived macrophages, (D) T cells
- 435
- 436 **Supplementary Data S6:** CellChat results for ligand-receptor pairs in TA scRNASeq from the
- 437 COMET cohort for (A) hyperinflammatory ARDS and (B) hypoinflammatory ARDS.
- 438
- 439 **Supplementary Data S7: (**A) Z-scaled O-link protein concentrations for five hyperinflammatory
- 440 ARDS, 20 hypoinflammatory ARDS, and 14 control subjects. (B) Results of Wilcoxon rank-sum
- 441 tests for pairwise comparisons of hyperinflammatory ARDS, hypoinflammatory ARDS, and
- 442 control subjects.
- 443

444

445 **References**

- 446 1 Matthay MA, Zemans RL, Zimmerman GA, *et al.* Acute respiratory distress syndrome. *Nature* 447 *Reviews Disease Primers* 2019; **5**: 1–22.
- RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19.
 New England Journal of Medicine 2021; **384**: 693–704.
- 450 3 RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID451 19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021; **397**:
 452 1637–45.
- 453 4 Beitler JR, Thompson BT, Baron RM, *et al.* Advancing precision medicine for acute 454 respiratory distress syndrome. *Lancet Respir Med* 2021; : S2213-2600(21)00157-0.
- 455 5 Calfee CS, Delucchi K, Parsons PE, *et al.* Subphenotypes in acute respiratory distress
 456 syndrome: latent class analysis of data from two randomised controlled trials. *The Lancet*457 *Respiratory Medicine* 2014; **2**: 611–20.
- Famous KR, Delucchi K, Ware LB, *et al.* Acute respiratory distress syndrome subphenotypes
 respond differently to randomized fluid management strategy. *American Journal of Respiratory and Critical Care Medicine* 2017; **195**: 331 338.
- 461 7 Sinha P, Delucchi KL, Thompson BT, McAuley DF, Matthay MA, Calfee CS. Latent class
 462 analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured
 463 lungs from sepsis (SAILS) study. *Intensive Care Medicine* 2018; **44**: 1859–69.
- Sinha P, Delucchi KL, Chen Y, *et al.* Latent class analysis-derived subphenotypes are
 generalisable to observational cohorts of acute respiratory distress syndrome: a prospective
 study. *Thorax* 2021; published online July 5. DOI:10.1136/thoraxjnl-2021-217158.
- 467 9 Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. *The Lancet* 2021;
 398: 622–37.
- 469 10Maddali MV, Churpek M, Pham T, *et al.* Validation and utility of ARDS subphenotypes
 470 identified by machine-learning models using clinical data: an observational, multicohort,
 471 retrospective analysis. *Lancet Respir Med* 2022; **10**: 367–77.
- 472 11 Calfee CS, Delucchi KL, Sinha P, *et al.* Acute respiratory distress syndrome subphenotypes
 473 and differential response to simvastatin: secondary analysis of a randomised controlled trial.
 474 *Lancet Respir Med* 2018; **6**: 691–8.
- 475 12Sinha P, Furfaro D, Cummings MJ, *et al.* Latent Class Analysis Reveals COVID-19–related
 476 Acute Respiratory Distress Syndrome Subgroups with Differential Responses to
 477 Corticosteroids. *Am J Respir Crit Care Med* 2021; **204**: 1274–85.
- 478 13Chen H, Xie J, Su N, *et al.* Corticosteroid Therapy Is Associated With Improved Outcome in
 479 Critically III Patients With COVID-19 With Hyperinflammatory Phenotype. *Chest* 2021; **159**:
 480 1793–802.

- 481 14Sinha P, Delucchi KL, McAuley DF, O'Kane CM, Matthay MA, Calfee CS. Development and
- 482 validation of parsimonious algorithms to classify acute respiratory distress syndrome
- 483 phenotypes: a secondary analysis of randomised controlled trials. *Lancet Respir Med* 2020;
 484 8: 247–57.
- 485
 485
 486
 486
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
- 488
 489
 489
 480
 480
 490
 490
 491
 492
 493
 494
 494
 495
 496
 496
 497
 498
 498
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
- 491 17ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. *JAMA* 492 2012; **307**: 2526–33.
- 493 18Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–
 494 associated infection and criteria for specific types of infections in the acute care setting.
 495 American Journal of Infection Control 2008; 36: 309–32.
- 496
 497 19 Sinha P, Churpek MM, Calfee CS. Machine Learning Classifier Models Can Identify Acute
 497 Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data. *Am J*498 *Respir Crit Care Med* 2020; **202**: 996–1004.
- 20Tsitsiklis A, Zha B, Byrne A, *et al.* Impaired immune signaling and changes in the lung
 microbiome precede secondary bacterial pneumonia in COVID-19. *Res Sq* 2021; published
 online April 23. DOI:10.21203/rs.3.rs-380803/v1.
- 502 21 Jin S, Guerrero-Juarez CF, Zhang L, *et al.* Inference and analysis of cell-cell communication
 503 using CellChat. *Nat Commun* 2021; **12**: 1088.
- 22Combes AJ, Courau T, Kuhn NF, *et al.* Global absence and targeting of protective immune
 states in severe COVID-19. *Nature* 2021; **591**: 124–30.
- S06 23Gundersen GW, Jones MR, Rouillard AD, *et al.* GEO2Enrichr: browser extension and server
 app to extract gene sets from GEO and analyze them for biological functions. *Bioinformatics* S08 2015; **31**: 3060–2.
- 24Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and
 RNA-Seq data. *BMC Bioinformatics* 2013; 14: 7.
- 511 25Ritchie ME, Phipson B, Wu D, *et al.* limma powers differential expression analyses for RNA-512 sequencing and microarray studies. *Nucleic Acids Research* 2015; **43**: e47.
- 513 26Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy 514 and vaccine design. *Nat Rev Immunol* 2006; **6**: 595–601.
- 515 27Boyle AJ, Ferris P, Bradbury I, *et al.* Baseline plasma IL-18 may predict simvastatin treatment
 516 response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical
 517 trial. *Crit Care* 2022; **26**: 164.

- 518 28 Stanifer ML, Guo C, Doldan P, Boulant S. Importance of Type I and III Interferons at
- 519 Respiratory and Intestinal Barrier Surfaces. *Frontiers in Immunology* 2020; **11**.
- 520 https://www.frontiersin.org/articles/10.3389/fimmu.2020.608645 (accessed Dec 7, 2022).
- 521 29Caulfield AJ, Lathem WW. Disruption of Fas-Fas Ligand Signaling, Apoptosis, and Innate
 522 Immunity by Bacterial Pathogens. *PLOS Pathogens* 2014; **10**: e1004252.
- 523 30Lee J-U, Kim L-K, Choi J-M. Revisiting the Concept of Targeting NFAT to Control T Cell 524 Immunity and Autoimmune Diseases. *Frontiers in Immunology* 2018; **9**.
- 525 https://www.frontiersin.org/articles/10.3389/fimmu.2018.02747 (accessed Dec 7, 2022).
- 31 Walzer T, Bléry M, Chaix J, *et al.* Identification, activation, and selective in vivo ablation of
 mouse NK cells via NKp46. *Proceedings of the National Academy of Sciences* 2007; **104**:
 3384–9.
- 529 32Bauer S, Groh V, Wu J, *et al.* Activation of NK Cells and T Cells by NKG2D, a Receptor for 530 Stress-Inducible MICA. *Science* 1999; **285**: 727–9.
- 33Mantovani A, Garlanda C. Platelet-macrophage partnership in innate immunity and
 inflammation. *Nat Immunol* 2013; **14**: 768–70.
- 34Hu X, Li W-P, Meng C, Ivashkiv LB. Inhibition of IFN-γ Signaling by Glucocorticoids1. *The* Journal of Immunology 2003; **170**: 4833–9.
- 35 35 Aran D, Looney AP, Liu L, *et al.* Reference-based analysis of lung single-cell sequencing
 reveals a transitional profibrotic macrophage. *Nat Immunol* 2019; **20**: 163–72.
- 36Ye SQ, Simon BA, Maloney JP, *et al.* Pre–B-Cell Colony-enhancing Factor as a Potential
 Novel Biomarker in Acute Lung Injury. *Am J Respir Crit Care Med* 2005; **171**: 361–70.
- 37 Muzio M, Chinnaiyan AM, Kischkel FC, *et al.* FLICE, A Novel FADD-Homologous ICE/CED3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex. *Cell* 1996; **85**: 817–27.
- 38Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC
 chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse
 RENCA tumor. *J Immunol* 1998; **161**: 927–32.
- 39Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. CD5 Expression Is
 Developmentally Regulated By T Cell Receptor (TCR) Signals and TCR Avidity. *Journal of Experimental Medicine* 1998; **188**: 2301–11.
- 548 40Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and 549 phenotypes. *The Lancet* 2022; **400**: 1145–56.
- 41 Matthay MA, Zemans RL, Zimmerman GA, *et al.* Acute respiratory distress syndrome. *Nat Rev Dis Primers* 2019; **5**: 1–22.
- 42Yao C, Bora SA, Parimon T, *et al.* Cell-Type-Specific Immune Dysregulation in Severely III
 COVID-19 Patients. *Cell Reports* 2021; **34**: 108590.

- 43Bos LD, Schouten LR, van Vught LA, *et al.* Identification and validation of distinct biological
 phenotypes in patients with acute respiratory distress syndrome by cluster analysis. *Thorax* 2017; **72**: 876–83.
- 44Heijnen NFL, Hagens LA, Smit MR, *et al.* Biological subphenotypes of acute respiratory
 distress syndrome may not reflect differences in alveolar inflammation. *Physiological Reports* 2021; 9: e14693.
- 45Altemeier WA, Matute-Bello G, Gharib SA, Glenny RW, Martin TR, Liles WC. Modulation of
 Lipopolysaccharide-Induced Gene Transcription and Promotion of Lung Injury by Mechanical
 Ventilation. *The Journal of Immunology* 2005; **175**: 3369–76.
- 46 Stephens RS, Johnston L, Servinsky L, Kim BS, Damarla M. The tyrosine kinase inhibitor
 imatinib prevents lung injury and death after intravenous LPS in mice. *Physiol Rep* 2015; 3:
 e12589.
- 47 Yang J-W, Mao B, Tao R-J, *et al.* Corticosteroids alleviate lipopolysaccharide-induced
 inflammation and lung injury via inhibiting NLRP3-inflammasome activation. *Journal of Cellular and Molecular Medicine* 2020; 24: 12716–25.
- 48Zhang Y, Zhang H, Li S, Huang K, Jiang L, Wang Y. Metformin Alleviates LPS-Induced Acute
 Lung Injury by Regulating the SIRT1/NF-κB/NLRP3 Pathway and Inhibiting Endothelial Cell
 Pyroptosis. *Front Pharmacol* 2022; **13**: 801337.
- 49Felciano RM, Bavari S, Richards DR, *et al.* Predictive systems biology approach to broad spectrum, host-directed drug target discovery in infectious diseases. *Pac Symp Biocomput* 2013; : 17–28.
- 575 50Bernhard W, Haagsman HP, Tschernig T, et al. Conductive airway surfactant: surface-
- tension function, biochemical composition, and possible alveolar origin. *Am J Respir Cell Mol Biol* 1997; **17**: 41–50.

578

579 Acknowledgments:

580 **Funding**:

- 581 National Institutes of Health grant F32HL151117 (AS)
- 582 National Institutes of Health grant R35HL140026 (CSC)
- 583 National Institutes of Health grant 2R24AA019661-06A1 (CSC)
- 584 National Institutes of Health grant K23HL138461-01A1 (CRL)
- 585 National Institutes of Health grant U19AI1077439 (DJE, CSC)
- 586 University of California San Francisco ImmunoX CoLabs
- 587 Chan Zuckerberg Foundation 2019-202665
- 588 Genentech TSK-020586

589

590 Author contributions:

- 591 Conceptualization: AS, SAC, CSC
- 592 Formal analysis/software: AS, SAC, AOP, LPAN, EM, MVM, AB, KLK
- 593 Data curation: HZ, AJ, RG, SC, TD
- 594 Investigation: AS, BSZ, PS, JGW, FM, AL, ERS, ZML, RG, SC, PHS, TD, CL, KNK,
- 595 CMH, MAM, CRL, CSC
- 596 Visualization: AS
- 597 Funding acquisition: AS, CRL, DJE, CSC
- 598 Project administration: JLD, DJE, MFK, KNK, CMH, PGW, MAM, CRL, CSC
- 599 Supervision: SAC, CRL, CSC
- 600 Writing original draft: AS
- 601 Writing review & editing: All authors
- 603 **Competing interests:** Authors declare that they have no competing interests.

605 **Data and materials availability:**

- 606 Code for differential expression and scRNASeq analyses is available at
- 607 https://github.com/AartikSarma/ARDSPhenotypes
- 608

602

604

- 609 The processed gene count data are available from the National Center for Biotechnology
- 610 Information Gene Expression Omnibus database under accession code GSE200849. The raw
- 611 sequencing data used in this analysis are protected due to data privacy restrictions from the IRB
- 612 protocols governing patient enrollment in this study, which protect the release of raw genetic
- 613 sequencing data from those patients enrolled under a waiver of consent. Researchers who wish
- to obtain raw FASTQ files for the purposes of independently generating gene counts can
- 615 contact the corresponding author (aartik.sarma@ucsf.edu) to be added to the IRB protocols and
- 616 sign a materials transfer agreement from UCSF ensuring that the data will be securely stored
- 617 and only utilized for transcriptomic analyses.

8 Figure 1: Bulk RNA sequencing analyses of TA collected in the Acute Lung Injury in Critical Illness 19 cohort. (A) Upstream regulator z-scores based on IPA analysis of differential gene expression in pairwise 20 comparisons of tracheal aspirate bulk RNA sequencing in hyperinflammatory ARDS (N=10), hypoinflammatory 21 ARDS (N=31), and mechanically ventilated controls (N=5). A positive z-score indicates differential gene 22 expression is consistent with greater activation of the upstream regulator of gene expression in the first group 23 in each pairwise comparison. Circles identify upstream regulators that are statistically significant. (B) Gene set 24 variation analysis for experimental models of lung injury. GSVA scores were calculated for each sample, and 25 the difference between hyperinflammatory ARDS and controls (orange) and hypoinflammatory ARDS and 26 controls (blue) was estimated with limma. For each model, the GEO Accession Number, organism, and lung 27 injury model are listed on the x-axis. (C) Upstream regulator scores for selected drugs in the IPA database that 28 are predicted to significantly shift gene expression away from hyperinflammatory ARDS in independent 29 analyses of differential gene expression with hypoinflammatory ARDS (blue) or controls (green). 30 Figure 2: TA single-cell RNA sequencing. (A) Seurat UMAP projection of 26,429 TA cell transcriptomes 31 from four participants with hyperinflammatory ARDS and five participants with hypoinflammatory ARDS, 32 annotated with cell type as predicted by SingleR. (B) UMAP projection of TA cells transcriptomes separated by 33 ARDS phenotype. (C) Differential interaction between cell types predicted by CellChat. Red arrows identify cell 34 pairs with greater strength of interaction in hyperinflammatory ARDS. (D) Differences in strength of ligand-35 receptor interaction for pathways in the CellChat database. (E) Upstream regulator analysis z-scores for 36 differentially expressed genes in neutrophils, monocytes, monocyte-derived macrophages, and T cells. A 37 positive z-score indicates the upstream regulator is predicted to be more highly activated in hyperinflammatory 38 ARDS. Circles identify upstream regulators that were statistically significant. 39 Figure 3: O-Link proteomics results for plasma biomarkers from 5 hyperinflammatory ARDS, 20 10 hypoinflammatory ARDS, and 14 control participants. Each heatmap shows plasma protein biomarkers 11 that were significantly different between groups (FDR < 0.1); for a complete list of proteins, see Supplementary

- ¹² Data S7. Each column represents an individual subject, and each row shows the z-scaled concentrations.
- 13 Rows and columns are clustered using the Euclidean distance. Columns are annotated by phenotype. Z-score
- 14 for expression is shown on the color bar on the right. (A) Hyperinflammatory ARDS vs. hypoinflammatory

- 45 ARDS (*: proteins that higher in hyperinflammatory ARDS vs. volunteers but not difference between
- 16 hypoinflammatory ARDS and controls; ‡: proteins that are higher in hyperinflammatory ARDS vs. volunteers
- 17 and lower in hypoinflammatory ARDS vs. volunteers) (B) Hyperinflammatory ARDS vs. healthy volunteers. (C)
- 18 Hypoinflammatory ARDS vs. healthy volunteers.

	Hyperinflammatory	Hypoinflammatory	P (1)	Control	P (2)	P (3)
Ν	10	31		5		
Age	66 [56, 72]	63 [51, 70]	0.63	66 ± 23	0.85	0.42
Female	4 (40)	21 (68)	0.95	3 (60)	0.26	0.49
BMI (kg/m²)	25.0 [23.6, 25.6]	25.9 [23.9, 32.2]	0.27	25.7 ± 4.8	0.24	0.23
Vasopressors at enrollment	9 (90)	19 (61)	0.19	1 (20)	<0.01	0.21
Minimum PF ratio (mmHg)	76 [62, 97]	93 [67, 138]	0.25	296 [216,366]	<0.01	<0.01
SOFA score at enrollment	18 [16, 19]	9 [7, 11]	<0.01	5 [4, 5]	<0.01	<0.01
IL-8, pg/ml	424 [228, 1068]	15 [9, 25]	<0.01	10 [8, 11]	<0.01	0.21
Protein C, % control	51 [31, 62]	103 [76, 132]	<0.01	115 [79, 148]	<0.01	0.76
Immunosuppression	4 (40)	6 (19)	0.37			
Primary ALI Risk Factor			0.79			
Pneumonia	4 (40)	16 (48)				
Sepsis	4 (40)	7 (23)				
Aspiration	2 (20)	6 (23)				
Pancreatitis	0 (0)	1 (3)				
None	0 (0)	1 (3)				
Clinical respiratory microbiology						
Respiratory viral pathogen	1 (10)	1 (3)	0.98			
Respiratory bacterial pathogen	3 (30)	11 (36)	1.00			

649

650 **Table 1:** Characteristics of patients included in differential expression analysis of ARDS phenotypes from the Acute Lung Injury in

651 Critical Illness cohort. Normally distributed values are reported as mean ± SD. Non-normally distributed values are reported as

652 median [IQR]. Categorical data are reported as N (% of total for category). P-values are for a t-test for normally distributed

- 653 continuous data, Wilcoxon rank-sum for non-normally distributed, and chi-square test for categorical data. P values are for (1)
- 654 hyperinflammatory ARDS vs. hypoinflammatory ARDS; (2) hyperinflammatory ARDS vs. controls; (3) hypoinflammatory ARDS vs.

655 controls

656

Α



B









